Dermatitis, Atopic – Talk Bio

Actionable Insights Powered by AI

Sanofi Increases Investment in Nurix-Partnership for STAT6 Program

5 days ago talkbio0Tagged Asthma, biotech collaboration, DEL-AI, Dermatitis, Atopic, Drug Discovery, Licensing Deal, Nurix, NX-3911, protein degrader, sanofi, STAT6

Sanofi; Nurix Therapeutics; STAT6; NX-3911; protein degrader; atopic dermatitis; asthma; drug discovery; licensing deal; DEL-AI platform; biotech collaboration

Galderma’s Nemluvio Secures Dual EU Approvals for Atopic Dermatitis and Prurigo Nodularis

4 months ago talkbio0Tagged Commission approval, Dermatitis, Atopic, European (ethnic group), Galderma, IL-31 receptor alpha, Monoclonal Antibodies, Nemluvio, nemolizumab, nodularis, Prurigo

Nemluvio, nemolizumab, Galderma, European Commission approval, atopic dermatitis, prurigo nodularis, IL-31 receptor alpha, monoclonal antibody

Allakos Announces Discontinuation of AK006 Program and 75% Layoffs Following Clinical Trial Failures

4 months ago talkbio0Tagged AK006, Allakos, chronic, Clinical Trials, Dermatitis, Atopic, Failure (biologic function)

Allakos, AK006, clinical trial failure, layoffs, biotech, chronic spontaneous urticaria, atopic dermatitis

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

6 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement

FDA Approves Expanded Use of VTAMA and Nemluvio for Atopic Dermatitis Treatment

6 months ago talkbio0Tagged Approved, Dermatitis, Atopic, Dermatologic disorders, Dermatology field, Galderma, Nemluvio, Organon, United States Food and Drug Administration, Vtama

FDA approval, atopic dermatitis, VTAMA, Nemluvio, Galderma, Organon, dermatology, skin conditions

Johnson & Johnson Expands Immunology Portfolio with $1.25B Acquisition of Yellow Jersey Therapeutics

7 months ago talkbio0Tagged Antibodies, Bispecific, Dermatitis, Atopic, Immunology, Johnson and Johnson, NM26, Numab, Yellow Jersey Therapeutics

Johnson & Johnson, Yellow Jersey Therapeutics, NM26, atopic dermatitis, bispecific antibody, immunology, Numab Therapeutics

Organon Expands Dermatology Portfolio with $1.2B Acquisition of Dermavant and VTAMA Cream

9 months ago talkbio0Tagged Acquisition (action), Dairy Cream, Dental Plaque, Dermatitis, Atopic, Dermatology field, Dermavant, Organon, Psoriasis, steroid-free skin cream, Vtama

Organon, Dermavant, VTAMA cream, dermatology, acquisition, steroid-free skin cream, plaque psoriasis, atopic dermatitis

Organon Expands Dermatology Portfolio with Acquisition of Dermavant for Up to $1.2 Billion

9 months ago talkbio0Tagged Acquisition (action), Dairy Cream, Dental Plaque, Dermatitis, Atopic, Dermatology field, Dermavant, Organon, Psoriasis, Roivant, tapinarof, Vtama

Organon, Dermavant, Roivant, dermatology, VTAMA cream, tapinarof, plaque psoriasis, atopic dermatitis, acquisition

FDA Approves Lilly’s Ebglyss for Moderate-to-Severe Atopic Dermatitis

9 months ago talkbio0Tagged Approved, biology (field), Dermatitis, Atopic, Ebglyss, Eczema, Eli, Eli Lilly, lebrikizumab, United States Food and Drug Administration

Ebglyss, atopic dermatitis, eczema, FDA approval, Eli Lilly, lebrikizumab, biologic treatment

FDA Approves Ebglyss (Lebrikizumab-lbkz) for Moderate-to-Severe Atopic Dermatitis in Adults and Children 12 Years and Older

9 months ago talkbio0Tagged Approved, Dermatitis, Atopic, Ebglyss, Eczema, Lebrikizumab-lbkz, United States Food and Drug Administration

Ebglyss, Lebrikizumab-lbkz, FDA Approval, Moderate-to-Severe Atopic Dermatitis, Eczema Treatment